When protein destruction runs amok, malignancy is on the loose

Cancer Cell

Volumn 4, Issue 4, 2003, Pages 251-256

  Pagano, Michele ^a   Benmaamar, Ramla ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; BETA TRANSDUCIN REPEAT CONTAINING PROTEIN; BORTEZOMIB; F BOX PROTEIN; MYC PROTEIN; PROTEASOME; PROTEASOME INHIBITOR; PROTEIN; UBIQUITIN PROTEIN LIGASE; UNCLASSIFIED DRUG;

AUTOSOMAL DOMINANT DISORDER; BREAST CANCER SUSCEPTIBILITY GENE 1; CANCER; CANCER THERAPY; CARCINOGENESIS; ENZYME ACTIVITY; FAMILIAL CANCER; GENE INACTIVATION; HUMAN; MURINE DOUBLE MINUTE 2 GENE; MYELOMA; ONCOGENE; PRIORITY JOURNAL; PROTEIN DEFECT; PROTEIN DEGRADATION; PROTEIN TARGETING; REVIEW; TUMOR SUPPRESSOR GENE; VON HIPPEL LINDAU DISEASE;

MAMMALIA; MURINAE;

EID: 0142165038     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1535-6108(03)00243-5     Document Type: Review

References (48)

1. Adams J. The proteasome. structure, function, and role in the cell Cancer Treat. Rev. 29(Suppl. 1):2003;3-9.
2. Baer R., Ludwig T. The BRCA1/BARD1 heterodimer, a tumor suppressor complex with ubiquitin E3 ligase activity. Curr. Opin. Genet. Dev. 12:2002;86-91.
3. Bartek J., Lukas J. Cell cycle. Order from destruction. Science. 294:2001;66-67.
4. Bies J., Wolff L. Oncogenic activation of c-Myb by carboxyl-terminal truncation leads to decreased proteolysis by the ubiquitin-26S proteasome pathway. Oncogene. 14:1997;203-212.
5. Bloom J., Pagano M. Deregulated degradation of the cdk inhibitor p27 and malignant transformation. Semin. Cancer Biol. 13:2003;41-47.
6. Boxer L.M., Dang C.V. Translocations involving c-myc and c-myc function. Oncogene. 20:2001;5595-5610.
7. Brown J.P., Pagano M. Mechanism of p53 degradation. Biochim. Biophys. Acta. 1332:1997;O1-O6.
8. Chen L.C., Manjeshwar S., Lu Y., Moore D., Ljung B.M., Kuo W.L., Dairkee S.H., Wernick M., Collins C., Smith H.S. The human homologue for the Caenorhabditis elegans cul-4 gene is amplified and overexpressed in primary breast cancers. Cancer Res. 58:1998;3677-3683.
9. Chene P. Inhibiting the p53-MDM2 interaction. an important target for cancer therapy Nat. Rev. Cancer. 3:2003;102-109.
10. Citri A., Alroy I., Lavi S., Rubin C., Xu W., Grammatikakis N., Patterson C., Neckers L., Fry D.W., Yarden Y. Drug-induced ubiquitylation and degradation of ErbB receptor tyrosine kinases. implications for cancer therapy EMBO J. 21:2002;2407-2417.
11. Conaway R.C., Conaway J.W. The von Hippel-Lindau tumor suppressor complex and regulation of hypoxia-inducible transcription. Adv. Cancer Res. 85:2002;1-12.
12. Dawson S., Apcher S., Mee M., Higashitsuji H., Baker R., Uhle S., Dubiel W., Fujita J., Mayer R.J. Gankyrin is an ankyrin-repeat oncoprotein that interacts with CDK4 kinase and the S6 ATPase of the 26 S proteasome. J. Biol. Chem. 277:2002;10893-10902.
13. Dowen S.E., Neutze D.M., Pett M.R., Cottage A., Stern P., Coleman N., Stanley M.A. Amplification of chromosome 5p correlates with increased expression of Skp2 in HPV-immortalized keratinocytes. Oncogene. 22:2003;2531-2540.
14. Ellis M., Chew Y.P., Fallis L., Freddersdorf S., Boshoff C., Weiss R.A., Lu X., Mittnacht S. Degradation of p27(Kip) cdk inhibitor triggered by Kaposi's sarcoma virus cyclin-cdk6 complex. EMBO J. 18:1999;644-653.
15. Grasser F.A., Graf T., Lipsick J.S. Protein truncation is required for the activation of the c-myb proto-oncogene. Mol. Cell. Biol. 11:1991;3987-3996.
16. Hainaut P., Hollstein M. p53 and human cancer. the first ten thousand mutations Adv. Cancer Res. 77:2000;81-137.
17. Hershko A., Ciechanover A. The ubiquitin system. Annu. Rev. Biochem. 67:1998;425-479.
18. Hideshima T., Anderson K.C. Molecular mechanisms of novel therapeutic approaches for multiple myeloma. Nat. Rev. Cancer. 2:2002;927-937.
19. Higashitsuji H., Itoh K., Nagao T., Dawson S., Nonoguchi K., Kido T., Mayer R.J., Arii S., Fujita J. Reduced stability of retinoblastoma protein by gankyrin, an oncogenic ankyrin-repeat protein overexpressed in hepatomas. Nat. Med. 6:2000;96-99.
20. Jin J., Harper J.W. A license to kill. Transcriptional activation and enhanced turnover of Myc by the SCFSkp2 ubiquitin ligase Cancer Cell. 3:2003;517-518.
21. Kaelin W.G. Jr. Molecular basis of the VHL hereditary cancer syndrome. Nat. Rev. Cancer. 2:2002;673-682.
22. Lai E.C. Protein degradation. four E3s for the notch pathway Curr. Biol. 12:2002;R74-R78.
23. LeBlanc R., Catley L.P., Hideshima T., Lentzsch S., Mitsiades C.S., Mitsiades N., Neuberg D., Goloubeva O., Pien C.S., Adams J.et al. Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res. 62:2002;4996-5000.
24. Luker G.D., Pica C.M., Song J., Luker K.E., Piwnica-Worms D. Imaging 26S proteasome activity and inhibition in living mice. Nat. Med. 9:2003;969-973.
25. Lynch H.T., de la Chapelle A. Hereditary colorectal cancer. N. Engl. J. Med. 348:2003;919-932.
26. Mann D.J., Child E.S., Swanton C., Laman H., Jones N. Modulation of p27(Kip1) levels by the cyclin encoded by Kaposi's sarcoma-associated herpesvirus. EMBO J. 18:1999;654-663.
27. Michael D., Oren M. The p53 and Mdm2 families in cancer. Curr. Opin. Genet. Dev. 12:2002;53-59.
28. Munger K., Basile J.R., Duensing S., Eichten A., Gonzalez S.L., Grace M., Zacny V.L. Biological activities and molecular targets of the human papillomavirus E7 oncoprotein. Oncogene. 20:2001;7888-7898.
29. Peschard P., Park M. Escape from Cbl-mediated downregulation. A recurrent theme for oncogenic deregulation of receptor tyrosine kinases. Cancer Cell. 3:2003;519-523.
30. Peters J.M. Emi1 proteolysis. how SCF(beta-Trcp1) helps to activate the anaphase-promoting complex Mol. Cell. 11:2003;1420-1421.
31. Philipp-Staheli J., Payne S.R., Kemp C.J. p27(Kip1). regulation and function of a haploinsufficient tumor suppressor and its misregulation in cancer Exp. Cell Res. 264:2001;148-168.
32. Pickart C.M. Mechanisms underlying ubiquitination. Annu. Rev. Biochem. 70:2001;503-533.
33. Polakis P. The oncogenic activation of beta-catenin. Curr. Opin. Genet. Dev. 9:1999;15-21.
34. Polakis P. Casein kinase 1. a Wnt'er of disconnect Curr. Biol. 12:2002;R499-R501.
35. Querido E., Blanchette P., Yan Q., Kamura T., Morrison M., Boivin D., Kaelin W.G., Conaway R.C., Conaway J.W., Branton P.E. Degradation of p53 by adenovirus E4orf6 and E1B55K proteins occurs via a novel mechanism involving a Cullin-containing complex. Genes Dev. 15:2001;3104-3117.
36. Richardson P. Clinical update. proteasome inhibitors in hematologic malignancies Cancer Treat. Rev. 29(Suppl 1):2003;33-39.
37. Roberts A., Wakefield L. The two faces of transforming growth factor β in carcinogenesis. Proc. Natl. Acad. Sci. USA. 100:2003;8621-8623.
38. Seagroves T., Johnson R.S. Two HIFs may be better than one. Cancer Cell. 1:2002;211-213.
39. Slingerland J., Pagano M. Regulation of the cdk inhibitor p27 and its deregulation in cancer. J. Cell. Physiol. 183:2000;10-17.
40. Soldatenkov V.A., Dritschilo A., Ronai Z., Fuchs S.Y. Inhibition of homologue of Slimb (HOS) function sensitizes human melanoma cells for apoptosis. Cancer Res. 59:1999;5085-5088.
41. Spruck C.H., Strohmaier H., Sangfelt O., Muller H.M., Hubalek M., Muller-Holzner E., Marth C., Widschwendter M., Reed S.I. hCDC4 gene mutations in endometrial cancer. Cancer Res. 62:2002;4535-4539.
42. Treier M., Staszewski L., Bohmann D. Ubiquitin-dependent c-Jun degradation in vivo is mediated by the ∂ domain. Cell. 78:1994;787-798.
43. Vandenberg C., Gergely F., Yi Ong C., Pace P., Mallery D., Hiom K., Patel K. BRCA1-independent ubiquitination of FANCD2. Mol. Cell. 12:2003;247-254.
44. Wang J., Chenivesse X., Henglein B., Brechot C. Hepatitis B virus integration in a cyclin A gene in a hepatocellular carcinoma. Nature. 343:1990;555-557.
45. Wang J., Zindy F., Chenivesse X., Lamas E., Henglein B., Brechot C. Modification of cyclin A expression by hepatitis B virus DNA integration in a hepatocellular carcinoma. Oncogene. 7:1992;1653-1656.
46. Wang W., Takimoto R., Rastinejad F., El-Deiry W.S. Stabilization of p53 by CP-31398 inhibits ubiquitination without altering phosphorylation at serine 15 or 20 or MDM2 binding. Mol. Cell. Biol. 23:2003;2171-2181.
47. Wilkinson K.D. Ubiquitination and deubiquitination. targeting of proteins for degradation by the proteasome Semin. Cell Dev. Biol. 11:2000;141-148.
48. Yokoi S., Yasui K., Saito-Ohara F., Koshikawa K., Iizasa T., Fujisawa T., Terasaki T., Horii A., Takahashi T., Hirohashi S., Inazawa J. A novel target gene, SKP2, within the 5p13 amplicon that is frequently detected in small cell lung cancers. Am. J. Pathol. 161:2002;207-216.